Regeneron Pharmaceuticals Inc

مادة اعلانية

Latest Update: 16 May 2025 23:59 Abu Dhabi Time.

Market Status: Closed

REGN

Regeneron Pharmaceuticals Inc

594.56

USD

9.570

1.64%

Open

588.23

Prev Close

584.99

PX_VOLUME

MARKET CAP (M)

DAY RANGE

581.49 - 595.19

52 WEEKS

520.50 - 1,211.20

Stock Statistics

Yearly Change

-38.60%

Listed Shares (Million)

136.10

Earnings Multiple

15.11

Average 30-day trading volume

782,955.00

Price-to-book ratio

2.19

Earnings Per Share

40.90

Previous Dividend Distribution

0.88

Dividend Yield

0.15%

Financial Summary

Quarterly
Annual

Income Statements

	Period Ending:	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023
Total Revenue		3,028.70	3,789.20	3,720.70	3,547.10	3,145.00	3,434.30	3,362.70
Gross Profit		2,564.40	3,350.10	3,229.60	3,066.90	2,711.20	3,019.60	2,926.30
Operating Income		604.00	1,145.80	1,243.70	1,108.10	773.80	1,105.20	1,211.00
Net Income		808.70	917.70	1,340.60	1,432.30	722.00	1,159.60	1,007.80
Profit Margin		26.70	24.22	36.03	40.38	22.96	33.77	29.97

	Period Ending:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Total Revenue		14,202.00	13,117.20	12,172.90	16,071.70	8,497.10
Gross Profit		12,357.80	11,403.70	10,871.20	13,865.90	7,377.20
Operating Income		4,271.40	4,335.50	5,252.70	9,222.50	3,566.60
Net Income		4,412.60	3,953.60	4,338.40	8,075.30	3,513.20
Profit Margin		31.07	30.14	35.64	50.25	41.35

Balance Sheet

	Period Ending:	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023
Total Assets		37,545.20	37,759.40	37,441.90	36,086.80	34,369.60	33,080.20	32,163.30
Total Liabilities		8,157.60	8,405.80	8,116.00	7,881.00	7,378.50	7,107.10	7,258.90
Total Equity		29,387.60	29,353.60	29,325.90	28,205.80	26,991.10	25,973.10	24,904.40

	Period Ending:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Total Assets		37,759.40	33,080.20	29,214.50	25,434.80	17,163.30
Total Liabilities		8,405.80	7,107.10	6,550.50	6,666.00	6,138.00
Total Equity		29,353.60	25,973.10	22,664.00	18,768.80	11,025.30

Cash Flows Statements

	Period Ending:	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023
Cash From Operating Activities		1,045.10	1,262.80	1,291.20	354.00	1,512.50	1,089.70	1,114.30
Cash From Investing Activities		647.50	350.60	-574.40	-557.20	-1,687.10	-66.20	-496.30
Cash From Financing Activities		-1,089.20	-1,135.50	-634.00	-478.10	47.10	-446.10	-407.30
Net Change in Cash		604.00	477.20	83.60	-681.60	-128.00	577.60	210.50

	Period Ending:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash From Operating Activities		4,420.50	4,594.00	5,014.90	7,081.30	2,618.10
Cash From Investing Activities		-2,468.10	-3,185.10	-3,784.60	-5,384.70	-70.60
Cash From Financing Activities		-2,200.50	-1,790.10	-1,009.00	-1,005.80	-1,970.50
Net Change in Cash		-248.80	-381.60	221.30	690.80	577.00

* In Million of United States Dollar

Reminder: The financial information on this website is delayed information that are originates from certified data providers in the financial markets, who retain the rights and intellectual property of this data, absolving ADMN of any responsibility.

REGN

Regeneron Pharmaceuticals Inc

ريجينيرون فارماسوتيكالز